Sharing Mono-Institutional Experience of Treating Pancreatic Cancer with Stereotactic Body Radiation Therapy (SBRT)

被引：1

作者：

Waheed, Asmara ^{[1
,2
,7
]}

Murland, Shannah ^{[3
]}

Yip, Eugene ^{[4
]}

Heikal, Amr ^{[4
]}

Ghosh, Sunita ^{[2
,5
,8
]}

Abraham, Aswin ^{[1
,2
]}

Paulson, Kim ^{[1
,2
]}

Tankel, Keith ^{[1
,2
]}

Usmani, Nawaid ^{[1
,2
]}

Severin, Diane ^{[1
,2
]}

Wong, Clarence ^{[6
]}

Joseph, Kurian ^{[1
,2
]}

机构：

[1] Univ Alberta, Dept Oncol, Div Radiat Oncol, Edmonton, AB T6G 1Z2, Canada

[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[3] Cross Canc Inst, Dept Radiat Therapy, Edmonton, AB T6G 1Z2, Canada

[4] Univ Alberta, Dept Oncol, Div Med Phys, Edmonton, AB T6G 1Z2, Canada

[5] Univ Alberta, Dept Oncol, Div Med Oncol, Edmonton, AB T6G 1Z2, Canada

[6] Univ Alberta, Dept Med, Div Gastroenterol, Edmonton, AB T6G 1Z2, Canada

[7] Allan Blair Canc Ctr, Dept Oncol, 4101 Dewdney Ave, Regina, SK S4T 7T1, Canada

[8] Henry Ford Hosp, Publ Hlth Sci, One Ford Pl, Detroit, MI 48202 USA

来源：

CURRENT ONCOLOGY | 2024年 / 31卷 / 10期

关键词：

pancreatic cancer; stereotactic body radiation therapy (SBRT); unresectable; PHASE-III; GEMCITABINE; RADIOTHERAPY; ADENOCARCINOMA; TRIAL; CHEMORADIOTHERAPY; RADIOSURGERY; SURVIVAL;

D O I：

10.3390/curroncol31100446

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Stereotactic body radiotherapy (SBRT) is an evolving treatment for the local management of pancreatic cancer (PC). The main purpose of this study is to report our initial experience in terms of local control (LC) and toxicity for PC patients treated with SBRT. Methods: We conducted a retrospective review of patients treated with SBRT using abdominal compression (AC) or an end-expiratory breath-holding (EEBH) technique. The median prescribed dose was 35 Gy, delivered in five fractions. Toxicities were recorded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and survival was estimated using the Kaplan-Meier method. Results: From 2017 to 2023, 17 PC patients were offered SBRT. Their median age was 69 years. The median follow-up from the date of diagnosis was 22.37 months. The overall survival (OS) was 94% at 1 year and 60.9% at 2 years. The progression-free survival (PFS) was 63.1% at 6 months and 56.1% at 9 months. The median OS was 26.3 months, and the median PFS was 20.6 months. The 6-month and 1-year LC rates were 71% and 50.8%, respectively. Conclusion: We are successful in implementing the SBRT program at our centre. SBRT appears to be a promising treatment option for achieving LC with limited acute toxicities.

引用

页码：5974 / 5986

页数：13

共 29 条

[1]

Chakraborty S, 2013, ANN GASTROENTEROL, V26, P346

[2] Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas [J].

Chang, Daniel T. ;

Schellenberg, Devin ;

Shen, John ;

Kim, Jeff ;

Goodman, Karyn A. ;

Fisher, George A. ;

Ford, James M. ;

Desser, Terry ;

Quon, Andrew ;

Koong, Albert C. .

CANCER, 2009, 115 (03) :665-672

[3] Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study [J].

Chauffert, B. ;

Mornex, F. ;

Bonnetain, F. ;

Rougier, P. ;

Mariette, C. ;

Bouche, O. ;

Bosset, J. F. ;

Aparicio, T. ;

Mineur, L. ;

Azzedine, A. ;

Hammel, P. ;

Butel, J. ;

Stremsdoerfer, N. ;

Maingon, P. ;

Bedenne, L. .

ANNALS OF ONCOLOGY, 2008, 19 (09) :1592-1599

[4] Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated [J].

Chuong, Michael D. ;

Springett, Gregory M. ;

Freilich, Jessica M. ;

Park, Catherine K. ;

Weber, Jill M. ;

Mellon, Eric A. ;

Hodul, Pamela J. ;

Malafa, Mokenge P. ;

Meredith, Kenneth L. ;

Hoffe, Sarah E. ;

Shridhar, Ravi .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (03) :516-522

[5] The systemic immunostimulatory effects of radiation therapy producing overall tumor control through the abscopal effect [J].

D'Andrea, Mark A. ;

Reddy, G. Kesava .

JOURNAL OF RADIATION ONCOLOGY, 2019, 8 (02) :143-156

[6] Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients [J].

Didolkar, Mukund S. ;

Coleman, Cardella W. ;

Brenner, Mark J. ;

Chu, Kyo U. ;

Olexa, Nicole ;

Stanwyck, Elizabeth ;

Yu, Airong ;

Neerchal, Nagaraj ;

Rabinowitz, Stuart .

JOURNAL OF GASTROINTESTINAL SURGERY, 2010, 14 (10) :1547-1559

[7] Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].

Ducreux, M. ;

Cuhna, A. Sa. ;

Caramella, C. ;

Hollebecque, A. ;

Burtin, P. ;

Goere, D. ;

Seufferlein, T. ;

Haustermans, K. ;

Van Laethem, J. L. ;

Conroy, T. ;

Arnold, D. .

ANNALS OF ONCOLOGY, 2015, 26 :V56-V68

[8] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[9]

Ghaly Maged, 2019, Pancreas (Fairfax), V3, P9, DOI 10.17140/POJ-3-110

[10] Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial [J].

Hammel, Pascal ;

Huguet, Florence ;

van Laethem, Jean-Luc ;

Goldstein, David ;

Glimelius, Bengt ;

Artru, Pascal ;

Borbath, Ivan ;

Bouche, Olivier ;

Shannon, Jenny ;

Andre, Thierry ;

Mineur, Laurent ;

Chibaudel, Benoist ;

Bonnetain, Franck ;

Louvet, Christophe .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (17) :1844-1853

← 1 2 3 →